Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with thiazolidinedione (TZD) alone or in combination with metformin. TZD dose stable for at least 120 days prior to screening, and those patients on metformin must have been on a stable dose for at least 30 days prior to screening.~* HbA1c between 7.1% and 10.0%, inclusive.~* Body mass index (BMI) between 25 kg/m\^2 and 45 kg/m\^2.~Exclusion Criteria:~* Patient previously in a study using exenatide or GLP-1 analogs.~* Treated with oral anti-diabetic medications other than TZD and metformin within 3 months of screening.~* Treated with oral insulin within 3 months of screening.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
- Placebo (Type: PLACEBO_COMPARATOR): After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).